Filaggrin Defect at Atopic Dermatitis: Modern Treatment Options
Nikolay N. Murashkin,
Leonid A. Opryatin,
Roman V. Epishev,
Alexander I. Materikin,
Eduard T. Ambarchian,
Roman A. Ivanov,
Alena A. Savelova,
Roza Y. Nezhvedilova,
Lyudmila L. Rusakova https://doi.org/10.15690/vsp.v21i5.2452
Abstract
Atopic dermatitis is a common chronic skin disease, its pathogenesis is associated with congenital or acquired deficiency of filaggrin protein. In recent years, extensive evidence on the causes of filaggrin deficiency has been obtained. The structure and functions of this protein are described, that opens new approaches for atopic dermatitis management.
Supporting agencies: Not specified
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests
Roman V. Epishev
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc, Celgene
Alexander I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc, Celgene
Eduard T. Ambarchian
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc, fees for scientific counseling from Johnson & Johnson
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests
Alena A. Savelova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests
Roza Y. Nezhvedilova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests
Lyudmila L. Rusakova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Author confirmed the absence of a reportable conflict of interests
References
1. Atopicheskii dermatit: Clinical guidelines. (In Russ). Доступно по: https://nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf. Ссылка активна на 24.09.2022.
2. Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):214–227. doi: https://doi.org/10.11613/bm.2019.0205
3. Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications. J Dermatol. 2014;41(3):205–212. doi: https://doi.org/10.1111/1346-8138.12317
4. Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):113–122. doi: https://doi.org/10.1016/j.iac.2016.08.007
5. Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–799. doi: https://doi.org/10.1016/j.jaci.2014.06.014
6. Dale BA, Presland RB, Lewis SP, et al. Transient Expression of Epidermal Filaggrin in Cultured Cells Causes Collapse of Intermed iate Filament Networks with Alteration of Cell Shape and Nuclear Integrity. J Invest Dermatol. 1997;108(2):179–187. doi: https://doi.org/10.1111/1523-1747.ep12334205
7. Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is in- ternalized and processed to correct filaggrin deficiency. J Invest Derm at ol. 2014;134(2):423–429. doi: https://doi.org/10.1038/jid.2013.284
8. McAleer MA, Jakasa I, Raj N, et al. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. Br J Dermatol. 2018;179(2):431–441. doi: https://doi.org/10.1111/bjd.16691
9. Garrett JP, Hoffstad O, Apter AJ, Margolis DJ. Racial comparison of filaggrin null mutations in asthmatic patients with atopic dermatitis in a US population. J Allergy Clin Immunol. 2013;132(5): 1232–1234. doi: https://doi.org/10.1016/j.jaci.2013.07.005
10. Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-offunction mutations. J Allergy Clin Immunol. 2014;134(4):867–875. doi: https://doi.org/10.1016/j.jaci.2014.08.011
11. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387: 1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-X
12. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011, 365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040
13. Brauweiler AM, Bin L, Kim BE, et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal a-toxin-induced keratinocyte death. J Allergy Clin Immunol. 2013;131:421–427. e1–e2. doi: https://doi.org/10.1016/j.jaci.2012.10.030
14. Seltmann J, Roesner LM, von Hesler FW, et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659–1661. doi: https://doi.org/10.1016/j.jaci.2015.01.048
15. Kim BE, Bin L, Ye YM, et al. IL-25 enhances HSV-1 replication by inhibiting filaggrin expression, and acts synergistically with Th2 cytokines to enhance HSV-1 replication. J Invest Dermatol. 2013;133:2678–2685. doi: https://doi.org/10.1038/jid.2013.223
16. Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol. 2015;136(1):205–208.e9. doi: https://doi.org/10.1016/j.jaci.2015.04.026
17. Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566
18. Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.e7. doi: https://doi.org/10.1016/j.jaci.2015.03.051
19. Wollenberg A, Ehmann LM. Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. Ann Dermatol. 2012;24(3):253. doi: https://doi.org/10.5021/ad.2012.24.3.253
20. Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. Clin Exp Allergy. 2018;48(8):919–934. doi: https://doi.org/10.1111/cea.13156
21. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: https://doi.org/10.1111/jdv.14891
22. Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–358. doi: https://doi.org/10.1016/j.jaci.2016.06.002
23. Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARbeta/ delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol. 2008;128(2):370–377. doi: https://doi.org/10.1038/sj.jid.5701026
24. Granato L. Modulator from fractions of vegetable unsaponifiables. Personal Care. 2012;09:69–72.
Review
For citations:
Murashkin N.N., Opryatin L.A., Epishev R.V., Materikin A.I., Ambarchian E.T., Ivanov R.A., Savelova A.A., Nezhvedilova R.Y., Rusakova L.L. Filaggrin Defect at Atopic Dermatitis: Modern Treatment Options. Current Pediatrics. 2022;21(5):347-351. (In Russ.) https://doi.org/10.15690/vsp.v21i5.2452
Views:
1511
Email this article 
